Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous monocyte-derived lysate-pulsed dendritic cells PV-001-DC

A cell-based cancer vaccine composed of autologous, monocyte-derived dendritic cells (mDCs) pulsed with tumor cell lysate containing tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration,the autologous tumor cell lysate-pulsed mDCs vaccine PV-001-DC may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the patient's tumor cell-specific TAAs, which may result in tumor cell lysis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous monocyte-derived lysate pulsed DCs PV-001-DC PV-001-dendritic cell
Code name:	PV-001-DC

autologous monocyte-derived lysate-pulsed dendritic cells PV-001-DC

Search NCI's Drug Dictionary